Logo-bi
Original Research
Jalil Pirayesh Islamian*, Mohsen Mohammadi, Behzad Baradaran, Alireza Farajollahi, Seyed Mahmoud Reza Aghamiri, Mohammad Asghari Jafarabadi, Haadi Karami, Amir Monfaredan, Dariuosh Shanehbandi
Bioimpacts. 2016;6(2): 93-98. doi: 10.15171/bi.2016.13
PMCID: PMC4981254     PMID: 27525226     Scopus ID: 84983516628    
Original Research
Keyvan Yousefi, Sanaz Hamedeyazdan, Darya Hodaei, Farzaneh Lotfipour, Behzad Baradaran, Mona Orangi, Fatemeh Fathiazad*
Bioimpacts. 2017;7(2): 75-82. doi: 10.15171/bi.2017.10
PMCID: PMC5524988     PMID: 28752071     Scopus ID: 85027462494    
Hypothesis
Mohammad Pourhassan-Moghaddam, Behrouz Farhadi, Kazem Nejati-Koshki*
Bioimpacts. 2012;2(1): 55-60. doi: 10.5681/bi.2012.007
PMCID: PMC3648915     PMID: 23678442     Scopus ID: 84876804823    
PDF
XML
Cited By:
Original Research
Soheila Rostami ORCID, Farzaneh Tafvizi* ORCID, Hamid Reza Kheiri Manjili
BioImpacts. 2022;12(4): 301-313. doi: 10.34172/bi.2021.23337
PMCID: PMC9376161     PMID: 35975200     Scopus ID: 85138644192    
The findings suggest that F-Lys-TMX NPs are more effective and have the potential for cell proliferation inhibition and apoptosis induction compared to the TMX. Hence, F-Lys-TMX NPs can be considered as an anti-cancer agent against MCF-7 breast cancer cells.


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge